Valirx is a semi-virtual, emerging biopharmaceutical company based in London and listed on the Alternative Investment Market. It is focused on the development and commercialisation of ground breaking and disruptive gene silencing technologies for the development of a novel class of oncology therapeutics and diagnostics. The Company operates through two subsidiaries: ValiPharma and ValiMedix. ValiPharma is developing GeneICE (Gene Inactivation by Chromatin Engineering), a novel DNA silencing technology platform able to silence cancer causing genes. GeneICE consists of two synthetic molecule constructs, an oligonucleotide and a gene repression peptide. GeneICE construct is an epigenetic alternative to antisense and RNAi technologies. GeneICE drug candidates and control molecules are currently undergoing efficacy and safety studies. The R&D pipeline includes 2 pre-clinical compounds Val101 and Val201. Vali101 development is being financed through the awarding of 1.2m by the EUREKA EuroStars programme, a Pan-European collaborative initiative. The consortium consists of PentaBase (Denmark) and GenoSyst (Finland) with ValiRx being the leader. ValiMedix is an e-commerce distribution platform selling Over-the-Counter SELF-test diagnostic screening kits.
WHY CHOOSE ED
"Many thanks to @equity_research for a superb Investor Forum. $BMK.L , $VLG.L & $VP.L all interesting companies. I recommend these events. "
"We cannot thank you enough for opening our eyes to private investors."
"MHP believes commissioned research is an important part of the toolkit to attract new investors and improve liquidity. We rate ED's analysts and research very highly as one of the leading providers in this space."
"One of the biggest problems private investors have, is getting access to broker research. It’s basically impossible for many investors. Therefore I feel some commissioned research is really important and a good investment for companies. In my experience ED are far more proactive than other firms in this space."
Blogger and Stockopedia Contributor
"There is a need now, more than ever before, for real insight and clarity to be brought to company messages for investors….I would strongly recommend Equity Development to the management of any company."
Small Cap Equity Salesman
"From early days as a private company through to being established on AIM, I have always been able to rely on ED for wise counsel, perceptive research and introductions to new, supportive shareholders."
"I would like to thank and congratulate you, particularly Liz, on your note. It’s short, sharp, pulls out the key issues and I believe will be a valuable asset for our retail outreach."
"The team at ED consistently produce high quality research and highlight profitable investment opportunities, an invaluable tool for small cap investors in this under researched space."
"I thoroughly enjoyed the investor evening again, and as before its good that you get such an interested audience who engage and ask us all decent questions."